Onkologie. 2026:20(2):74-77 | DOI: 10.36290/xon.2026.013

Current approaches to diagnosis and primary surgical management of tubo-ovarial cancer

Anna Germanová
Klinika gynekologie, porodnictví a neonatologie, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze

Ovarian cancer is one of the most serious gynecological malignancies, and despite advances in diagnostics and treatment, it remains a major cause of mortality among women. The disease is characterized by significant biological heterogeneity and is diagnosed at an advanced stage in most cases. This article summarizes current know­ledge regarding the epidemiology, risk factors, diagnosis, and primary treatment of tubo-ovarian cancer based on available clinical studies and recommendations from professional societies.

Keywords: tubo-ovarian cancer, cytoreductive surgery, HIPEC.

Accepted: April 20, 2026; Published: April 28, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Germanová A. Current approaches to diagnosis and primary surgical management of tubo-ovarial cancer. Onkologie. 2026;20(2):74-77. doi: 10.36290/xon.2026.013.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 28.4.2027

    References

    1. International Agency for Research on Cancer. Global Cancer Observatory: Cancer Today. Lyon: IARC; 2022.
    2. Available from: www.svod.cz.
    3. Wentzensen N, Poole EM, Trabert B, et al. Ovarian Cancer Risk Factors by Histologic Subtype: Analysis from the Ovarian Cancer Cohort Consortium. J Clin Oncol. 2016. Go to original source... Go to PubMed...
    4. Chen S, Permigiani G. Meta - analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329-1333. Go to original source... Go to PubMed...
    5. Chen J, Bae E, Zhang L, et al. Penetrance of breast and Ovarian Cancer in Women Who Carry a BRCA 1/2 Mutation and Do Not Use Risk - Reducing Salpingo-Oophorectomy: An updated metaanalysis. JCNI Cancer Spectr. 2020;4(4):pakaa029. Go to original source... Go to PubMed...
    6. Available from: www.onkogenetika.cz.
    7. Andreotti RF, Timmerman D, Strachowski LM, et al. O-RADS US Risk Stratification and Management System. Radiology. 2020;294(1):168-185. Go to original source...
    8. Fischerova D, Planchamp F, Alcázar JL, et al. ISUOG/ESGO Consensus Statement on ultrasound-guided biopsy in gynecologic oncology. Ultrasound Obstet Gynecol. 2025;65(4):517-535. Go to original source... Go to PubMed...
    9. Agusti N, Vivero-Carreno D, Grillo-Ardila C, et al. Sentinel Lymph Node Detection in Early-stage Ovarian Cancer: a Systematic review and Meta-analysis. Int J Gynecol Cancer. 2023;33(10):1493-1501. Go to original source... Go to PubMed...
    10. Du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical out­come as prognostic factor in advanced epithelial ovarian can­cer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicnter trials. Cancer. 2009;115(6):1234-1244. Go to original source... Go to PubMed...
    11. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943-953. Go to original source...
    12. Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249-257. Go to original source...
    13. Onda T, Satoh T, Saito T, et al. Comparison of treatment invasiveness between upfront debulking surgery and interval debulking surgery following neoadjuvant chemotherapy following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. Eur J Cancer. 2020;130:114-125. Go to original source... Go to PubMed...
    14. Fagotti A, Ferrandina G, Vizzielli G, et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT 01461850). Int J Gynecol Cancer. 2020;30(11):1657-1664. Go to original source...
    15. Mahner S, et al. TRUST trial (ENGOT ov33/AGO-OVAR OP7): Trial of Radical Upfront Surgical Therapy in Advanced Ovarian Cancer. ASCO 2025. Go to original source...
    16. Harter P, Sehouli J, Lorusso D, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Eng J Med. 2019;380(9):822-832. Go to original source... Go to PubMed...
    17. Lim MC, Chang SJ, Park B, et al. Survival After Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in Ovarian Cancer. JAMA Surg. 2022;157(5):374-383. doi: 10.1001/jamasurg.2022.0143. PMID: 35262624; PMCID: PMC8908225. Go to original source... Go to PubMed...
    18. Cascales-Campos PA, Gonzales GA, Gil Gomez E, et al. Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer. Ann Surg Oncol. 2022;29(4):2617-2625. Go to original source...
    19. van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer (OVHIPEC-1). N Engl J Med. 2018;378:230-240. Go to original source...
    20. Koole S, van Stein R, Sikorska K, et al. Primary cytoreductive surgery with or without hypertermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. Int J Gynecol Cancer. 2020;30(6):888-892. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.